General
Preferred name
ADAPALENE
Synonyms
ICX5609064 ()
CD271 ()
PMID27336223-Compound-11 ()
Adapalene sodium salt ()
Adapalene (sodium salt) ()
CD 271 sodium salt ()
CD-271 ()
ADAPALENE COMPONENT OF CABTREO ()
ADAPALENE COMPONENT OF EPIDUO ()
ADAPALENE COMPONENT OF IDP-126 ()
ADAPALENO ()
CD 271 ()
Differin ()
Adapalene-d3 ()
P&D ID
PD001297
CAS
106685-40-9
911110-93-5
1276433-89-6
Tags
available
drug
Approved by
FDA
First approval
1996
Drug indication
acne
Acne vulgaris
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Adapalene is a third-generation topical anti-acne retinoid.
(GtoPdb)
ABSORPTION
Adapalene displays a limited absorption potential across the human skin. Only trace amounts (<0.25 ng/mL) of parent substance have been found in the plasma of acne patients following chronic topical application of adapalene in controlled clinical trials
PRICE
29
DESCRIPTION
Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RAR¦Â, RAR¦Ã, RAR¦Á, respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity[1][2][3].
DESCRIPTION
Mineralocorticoid receptor antagonist
(Tocris Bioactive Compound Library)
DESCRIPTION
RARbeta and RARgamma agonist
(Tocriscreen Plus)
DESCRIPTION
Adapalene (CD271) is a dual RAR and RXR agonist, utilized in the treatment of skin conditions.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Adapalene sodium salt, a synthetic retinoid, is a Retinoic acid receptor agonist (RAR). It is a third-generation topical retinoid primarily used in the treatment of mild-moderate acne and is also used (off-label) to treat keratosis pilaris as well as other skin conditions. It is possibly more effective than tretinoin 0.025% gel in the treatment of acne vulgaris.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
32
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
165
Molecular Weight
412.2
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
7
Aromatic Ring Count
3
cLogP
6.68
TPSA
46.53
Fraction CSP3
0.39
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target Type
Nuclear Receptors
Pathway
Apoptosis
Autophagy
Metabolism
Metabolic Enzyme/Protease
Vitamin D Related/Nuclear Receptor
Primary Target
Retinoic Acid Receptors
MOA
Agonist
Retinoid Receptor agonist
Target
RARA, RARB, RARG, RXRA, RXRB, RXRG
Retinoid Receptor
RAR/RXR
RAR
RXR
Indication
acne vulgaris (AV)
Therapeutic Class
Dermatologic Agents
Solubility
Soluble in DMSO (Slightly), Methanol (Slightly)
Recommended Cell Concentration
1 uM
Source data

